We’re proud to share groundbreaking results from an ongoing CAR T-cell therapy trial in children with diffuse midline gliomas (DMG), a class of lethal brain and spinal cord tumors, led by Dr. Crystal Mackall and Dr. Michelle Monje at Stanford and recently published in?Nature. CureSearch awarded Dr. Mackall a Catapult Award in 2019 to support this work, and the impact is inspiring. To date, 11 patients have been treated, with 9 regaining abilities impacted by their tumors, including hearing and walking; in 4 patients, tumors shrank by over half. One patient, Drew, remains tumor-free four years after his diagnosis of diffuse intrinsic pontine glioma (DIPG), a subtype of DMG—a remarkable milestone given that the 5-year survival rate of DIPG is less than 1%. This trial represents a significant advancement in CAR T-cell therapy for solid tumors, offering new hope for patients and families affected by DMG and DIPG everywhere. Read the full article here: https://lnkd.in/g9gCdqVv
CureSearch for Children's Cancer
非营利组织管理
Uniquely positioned to accelerate the pace of pediatric drug development. We're on a mission to end children's cancer.
关于我们
For more than 30 years, CureSearch has been a driving force in pediatric cancer research. Recognizing a broken system, growing obstacles, and unmet needs in drug development, we’ve launched an innovative and unique strategy to address the urgent, critical need for new childhood cancer treatments. By supporting CureSearch, you’re funding research that’s on the path to quickly becoming a drug accessible to the children who so desperately need new treatment options, and you’re providing innovative platforms that allow stakeholders to work smarter, faster and more collaboratively. With the expert leadership of our Scientific and Industry Advisory Councils, we identify and fund only the strongest research projects that address areas of unmet need and are most likely to quickly reach patients in the clinic or marketplace. We create connections and community between stakeholders by providing platforms for engagement to allow critical conversations to occur. CureSearch stakeholder meetings such as the annual CureSearch Summit and first-of-its-kind IMPACT Series directly influence and advance pediatric cancer research and drug development. Together, we’re changing the drug development landscape from within and accelerating the development of new treatments for the 42 children diagnosed with cancer each day.
- 网站
-
https://www.curesearch.org
CureSearch for Children's Cancer的外部链接
- 所属行业
- 非营利组织管理
- 规模
- 11-50 人
- 总部
- Remote
- 类型
- 非营利机构
- 创立
- 1987
- 领域
- Children's Cancer、Research、Strategic Partnerships、Education and Resources for Families、Fundraising、Coping with Cancer和drug development
地点
-
主要
获取路线
US，Remote
CureSearch for Children's Cancer员工
-
Mike Crowe
Retired CIO; Board Member; Advisor; Co-Founder, Team Steve: The Steven Crowe Legacy Fund at CureSearch for Children's Cancer
-
Ali Frost
Chief Marketing Officer
-
Heidi Price
Manager, Non-profit Donor Services and Relations
-
Tina Swallow
Sales Leader, Veteran, Advisor, Board Member, and Mentor
动态
-
It is our pleasure to welcome Matthew Thompson, of Matthew Thompson Law Group as our Board Chair for the Houston Leadership Board. Matthew will be instrumental in changing the outcome for the 42 children a day diagnosed with pediatric cancer. Matt is a dedicated litigation attorney focused on personal injury cases, known for his client-centered approach and commitment to achieving results. Before attending Harvard Law School, he served as an Officer and pilot in the United States Marine Corps and continues to serve as a reservist, recently earning the rank of Lieutenant Colonel. Based in Houston, Matt enjoys time with family and friends, and shares his home with his dog, Tex. Find out more about our Community Leadership Boards on our website at https://lnkd.in/gHv59Dmw
-
-
Welcome Eric Jacuzzi of NASCAR, to the CureSearch Charlotte Leadership Board! Eric’s passionate leadership will drive forward our mission to end childhood cancer. Thank you for generously contributing your time and expertise to further our mission! Learn more about our Community Leadership Board program at https://lnkd.in/g43sTsj2
-
-
Our Ultimate Hikers are nothing short of incredible! ?? #onthetrailtoacure #acceleratingthepace #endchildrenscancer #curesearchultimatehike
Frank Gioscia, 73, raises $500k through CureSearch Ultimate Hike
themountainpress.com
-
Ultimate Hiker, Frank Gioscia, just hit a record-breaking milestone, raising over $500,000 for childhood cancer research! He’s officially our first-ever 10X Everest Award recipient, and this Saturday, he’ll lace up for the Foothills Fall Ultimate Hike to close out an incredible 2024 season. Join us in celebrating Frank’s unwavering commitment to funding cures! ???? #UltimateHike #ChildhoodCancerResearch
Ultimate Hiker Frank Gioscia raises $500K for Childhood Cancer Research
curesearch.org
-
We’re thrilled to share news that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GD2-CAR T-cell therapy for diffuse midline gliomas (DMG), a groundbreaking development led by Dr. Crystal Mackall, a CureSearch Catapult Awardee, and Dr. Michelle Monje. DMGs are aggressive pediatric cancers with no approved treatments beyond palliative care, making this designation a significant step forward. The trial, co-funded by CureSearch for Children's Cancer and Parker Institute for Cancer Immunotherapy, and conducted at Stanford Children's Health, has yielded impressive early results, including substantial tumor shrinkage and improved neurological function. One child even achieved a complete response lasting over three years. An upcoming publication of the study’s findings will be available soon. RMAT is a special status granted by the FDA to expedite the development and approval of certain therapies. This RMAT designation enhances collaboration with the FDA, aligning with our mission to accelerate access to innovative therapies for children with cancer, especially those cancers with high unmet need. Congratulations to Drs. Mackall, Monje, and their dedicated team for their incredible work!
-
-
Welcome Amanda Jacobson to the CureSearch Colorado Leadership Board! Amanda’s passionate leadership will drive forward our mission to end childhood cancer. Thank you for generously contributing your time and expertise to further our mission! Learn more about our Community Leadership Board program at https://lnkd.in/g43sTsj2
-
-
We are profoundly inspired by the incredible community efforts highlighted in the Standard Banner article, "Walking Toward $500K." This story showcases the dedication of individuals like Frank Gioscia, who is participating in the Foothills Fall Ultimate Hike to help raise nearly half a million dollars for critical childhood cancer research. Fundraisers like the CureSearch Ultimate Hike are vital in advancing our mission, and we are deeply grateful to everyone who takes part. Together, we are making meaningful strides in the fight against childhood cancer. Read more here: https://lnkd.in/g3-tzHVJ
Walking toward $500K
https://www.standardbanner.com
-
It is our pleasure to welcome Dave Walton, CIPP-US, of Fisher Phillips as our Corporate Chair for the Philadelphia Leadership Board. Dave will be instrumental in changing the outcome for the 42 children a day diagnosed with pediatric cancer. Find out more about our Community Leadership Boards on our website at https://lnkd.in/gHv59Dmw
-
-
Today’s #peds2024 included insights from Julie Grant, General Partner Canaan and Chair of the Board of Directors at Day One Biopharmaceuticals, who emphasized the power of collaboration across industries. When we break down labels and embrace diverse expertise, we unlock new possibilities for innovation. It’s a reminder that none of us can do it alone—we all need each other to drive meaningful progress. – Learn more and join the conversation ?? curesearch.org/peds 2024 PEDS is presented by Day One Biopharmaceuticals
-